IBER + ibrutinib

IBER + ibrutinib is a combination therapy consisting of two small molecule drugs used in the treatment of B-cell malignancies, most notably chronic lymphocytic leukemia (CLL). "IBER" likely refers to iberdomide, an immunomodulatory agent, but there is no evidence in the provided sources or current literature that a combination of iberdomide and ibrutinib has been clinically developed or studied. The best-documented and widely studied combinations with ibrutinib are with venetoclax, rituximab, and obinutuzumab[1][4][5][7][8]. Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK), disrupting B cell receptor signaling critical for malignant B cell survival[1][3]. Combination regimens aim to improve response rates and overcome resistance seen with single-agent therapies. If "IBER" refers to another agent not currently recognized in clinical use or research as a partner for ibrutinib, then this combination may be investigational or incorrectly specified.